z-logo
open-access-imgOpen Access
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Author(s) -
Ryan K. Shields,
Liang Chen,
Shaoji Cheng,
Kalyan D. Chavda,
Ellen G. Press,
Avin C. Snyder,
Ruchi Pandey,
Yohei Doi,
Barry N. Kreiswirth,
M. Hong Nguyen,
Cornelius J. Clancy
Publication year - 2016
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02097-16
Subject(s) - ceftazidime/avibactam , klebsiella pneumoniae , avibactam , microbiology and biotechnology , carbapenem , ceftazidime , klebsiella infections , plasmid , carbapenem resistant enterobacteriaceae , enterobacteriaceae infections , enterobacteriaceae , medicine , virology , biology , antibiotics , escherichia coli , pseudomonas aeruginosa , bacteria , genetics , gene
Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistantEnterobacteriaceae (CRE) that produceKlebsiella pneumoniae carbapenemase (KPC). We report the first cases of ceftazidime-avibactam resistance to develop during treatment of CRE infections and identify resistance mechanisms. Ceftazidime-avibactam-resistantK. pneumoniae emerged in three patients after ceftazidime-avibactam treatment for 10 to 19 days. Whole-genome sequencing (WGS) of longitudinal ceftazidime-avibactam-susceptible and -resistantK. pneumoniae isolates was used to identify potential resistance mechanisms. WGS identified mutations in plasmid-bornebla KPC-3 , which were not present in baseline isolates.bla KPC-3 mutations emerged independently in isolates of a novel sequence type 258 sublineage and resulted in variant KPC-3 enzymes. The mutations were validated as resistance determinants by measuring MICs of ceftazidime-avibactam and other agents following targeted gene disruption inK. pneumoniae , plasmid transfer, andbla KPC cloning into competentEscherichia coli . In rank order, the impact of KPC-3 variants on ceftazidime-avibactam MICs was as follows: D179Y/T243M double substitution > D179Y > V240G. Remarkably, mutations reduced meropenem MICs ≥4-fold from baseline, restoring susceptibility inK. pneumoniae from two patients. Cefepime and ceftriaxone MICs were also reduced ≥4-fold against D179Y/T243M and D179Y variant isolates, but susceptibility was not restored. Reverse transcription-PCR revealed that expression ofbla KPC-3 encoding D179Y/T243M and D179Y variants was diminished compared tobla KPC-3 expression in baseline isolates. In conclusion, the development of resistance-conferringbla KPC-3 mutations inK. pneumoniae within 10 to 19 days of ceftazidime-avibactam exposure is troubling, but clinical impact may be ameliorated if carbapenem susceptibility is restored in certain isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom